These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 9815896)
1. Antibody to ras proteins in patients with colon cancer. Takahashi M; Chen W; Byrd DR; Disis ML; Huseby ES; Qin H; McCahill L; Nelson H; Shimada H; Okuno K Clin Cancer Res; 1995 Oct; 1(10):1071-7. PubMed ID: 9815896 [TBL] [Abstract][Full Text] [Related]
2. CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients. Qin H; Chen W; Takahashi M; Disis ML; Byrd DR; McCahill L; Bertram KA; Fenton RG; Peace DJ; Cheever MA Cancer Res; 1995 Jul; 55(14):2984-7. PubMed ID: 7606715 [TBL] [Abstract][Full Text] [Related]
3. [CD4+ T-cell immunity and Ab responses to mutant ras protein in pancreas and colon cancer patients]. Qin H; Chen W; Takahashi M Zhonghua Zhong Liu Za Zhi; 1996 May; 18(3):173-6. PubMed ID: 9387247 [TBL] [Abstract][Full Text] [Related]
4. T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes. Peace DJ; Chen W; Nelson H; Cheever MA J Immunol; 1991 Mar; 146(6):2059-65. PubMed ID: 2005390 [TBL] [Abstract][Full Text] [Related]
5. Mutant ras epitopes as targets for cancer vaccines. Abrams SI; Hand PH; Tsang KY; Schlom J Semin Oncol; 1996 Feb; 23(1):118-34. PubMed ID: 8607022 [TBL] [Abstract][Full Text] [Related]
6. Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer. Kubuschok B; Neumann F; Breit R; Sester M; Schormann C; Wagner C; Sester U; Hartmann F; Wagner M; Remberger K; Schilling M; Pfreundschuh M Clin Cancer Res; 2006 Feb; 12(4):1365-72. PubMed ID: 16489095 [TBL] [Abstract][Full Text] [Related]
7. Detection of activated Mr 21,000 protein, the product of ras oncogenes, using antibodies with specificity for amino acid 12. Wong G; Arnheim N; Clark R; McCabe P; Innis M; Aldwin L; Nitecki D; McCormick F Cancer Res; 1986 Dec; 46(12 Pt 1):6029-33. PubMed ID: 3490906 [TBL] [Abstract][Full Text] [Related]
8. Quantitation of Harvey ras p21 enhanced expression in human breast and colon carcinomas. Hand PH; Vilasi V; Thor A; Ohuchi N; Schlom J J Natl Cancer Inst; 1987 Jul; 79(1):59-65. PubMed ID: 3298786 [TBL] [Abstract][Full Text] [Related]
9. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide]. Yang B; He Y; Sun DL; Zou Y; Qin XH; Huang BH Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1956-60. PubMed ID: 19062734 [TBL] [Abstract][Full Text] [Related]
10. Ras p21 onco-protein in the sera of mice carrying an experimentally induced tumor and in human cancer patients. Kakkanas A; Spandidos DA In Vivo; 1990; 4(2):115-20. PubMed ID: 2129802 [TBL] [Abstract][Full Text] [Related]
11. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization. Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579 [TBL] [Abstract][Full Text] [Related]
12. Mutational and nonmutational activation of p21ras in rat colonic azoxymethane-induced tumors: effects on mitogen-activated protein kinase, cyclooxygenase-2, and cyclin D1. Bissonnette M; Khare S; von Lintig FC; Wali RK; Nguyen L; Zhang Y; Hart J; Skarosi S; Varki N; Boss GR; Brasitus TA Cancer Res; 2000 Aug; 60(16):4602-9. PubMed ID: 10969813 [TBL] [Abstract][Full Text] [Related]
13. Preparation, characterization and properties of monoclonal antibodies against intact H-ras p21 proteins. Sorrentino V; Nebreda AR; Alonso T; Santos E Oncogene; 1989 Feb; 4(2):215-22. PubMed ID: 2467247 [TBL] [Abstract][Full Text] [Related]
14. Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln-->Leu61). Gedde-Dahl T; Spurkland A; Eriksen JA; Thorsby E; Gaudernack G Int Immunol; 1992 Nov; 4(11):1331-7. PubMed ID: 1282032 [TBL] [Abstract][Full Text] [Related]
15. Genetic and epigenetic changes in p21 and p21B do not correlate with resistance to doxorubicin or mitomycin and 5-fluorouracil in locally advanced breast cancer. Staalesen V; Leirvaag B; Lillehaug JR; Lønning PE Clin Cancer Res; 2004 May; 10(10):3438-43. PubMed ID: 15161699 [TBL] [Abstract][Full Text] [Related]
16. Ki-ras codon 12 point and P53 mutations: a molecular examination of the main tumor, liver, portal vein, peripheral arterial blood and para-aortic lymph node in pancreatic cancer. Yamaguchi K; Chijiiwa K; Torato N; Kinoshita M; Tanaka M Am J Gastroenterol; 2000 Aug; 95(8):1939-45. PubMed ID: 10950039 [TBL] [Abstract][Full Text] [Related]
17. Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Ritter G; Cohen LS; Williams C; Richards EC; Old LJ; Welt S Cancer Res; 2001 Sep; 61(18):6851-9. PubMed ID: 11559561 [TBL] [Abstract][Full Text] [Related]
18. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung. Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992 [TBL] [Abstract][Full Text] [Related]
19. Mutated p53 protein expression and proliferative activity in advanced gastric cancer. Ikeguchi M; Saito H; Kondo A; Tsujitani S; Maeta M; Kaibara N Hepatogastroenterology; 1999; 46(28):2648-53. PubMed ID: 10522058 [TBL] [Abstract][Full Text] [Related]
20. p53 and p21/Waf1 protein expression and K-ras codon 12 mutation in carcinoma of the papilla of Vater. Zhao B; Kimura W; Futakawa N; Muto T; Kubota K; Harihara Y; Takayama T; Makuuchi M Am J Gastroenterol; 1999 Aug; 94(8):2128-34. PubMed ID: 10445539 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]